(Q24243827)

6

0 references

author name string

Jonathan C Ipser

1

0 references

Paul Carey

2

0 references

Yumna Dhansay

3

0 references

Nuraan Fakier

Cochrane Database of Systematic Reviews

4

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Citalopram for treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Quantitative analysis of sponsorship bias in economic studies of antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Treatment-resistant panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Measuring the quality of trials: the quality of quality scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The development of a Clinician-Administered PTSD Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Pharmacological treatment of social anxiety disorder: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The empirical status of cognitive-behavioral therapy: A review of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Psychological and pharmacological treatments of social phobia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Fixed Effects vs. Random Effects Meta-Analysis Models: Implications for Cumulative Research Knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Quality of life in individuals with anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Treatment non-response in OCD: methodological issues and operational definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Multicenter collaborative panic disorder severity scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005473.PUB2